The associations of hepatic steatosis and fibrosis using fatty liver index and BARD score with cardiovascular outcomes and mortality in patients with new-onset type 2 diabetes: a nationwide cohort study

Table 3 Risk of myocardial infarction, stroke, heart failure, and mortality according to BARD score in patients with fatty liver index (FLI) ≥ 60 compared to FLI < 60

	Event	Duration (person-years)	Incidence Rate^a	Hazard Ratio (95% CI)
	Event	Duration (person-years)	Incidence Rate^a	Model 1	Model 2
Myocardial infarction
FLI < 60	2008	704,631	2.85	1 (Ref)	1 (Ref)
FLI ≥ 60, BARD < 2	457	184,258	2.48	1.13 (1.02–1.26)	1.13 (1.00–1.27)
FLI ≥ 60, BARD ≥ 2	614	177,722	3.45	1.21 (1.11–1.33)	1.26 (1.14–1.40)
P for trend				< 0.001	< 0.001
Stroke
FLI < 60	2931	701,213	4.18	1 (Ref)	1 (Ref)
FLI ≥ 60, BARD < 2	490	184,039	2.66	1.02 (0.92–1.12)	1.13 (1.01–1.26)
FLI ≥ 60, BARD ≥ 2	817	176,836	4.62	1.16 (1.07–1.25)	1.26 (1.15–1.37)
P for trend				< 0.001	< 0.001
Heart failure
FLI < 60	4127	702,724	5.87	1 (Ref)	1 (Ref)
FLI ≥ 60, BARD < 2	724	184,297	3.93	1.11 (1.02–1.20)	1.10 (1.01–1.21)
FLI ≥ 60, BARD ≥ 2	1252	177,013	7.07	1.29 1.21–1.38)	1.31 (1.22–1.41)
P for trend				< 0.001	< 0.001
Mortality
FLI < 60	6191	710,862	8.71	1 (Ref)	1 (Ref)
FLI ≥ 60, BARD < 2	741	185,750	3.99	0.81 (0.75–0.87)	1.22 (1.23–1.33)
FLI ≥ 60, BARD ≥ 2	1533	179,567	8.54	1.03 (0.97–1.09)	1.48 (1.39–1.58)
P for trend				0.736	< 0.001

Model 1: Adjusted for age and sex
Model 2: Adjusted for age, sex, smoking status, alcohol consumption, regular exercise, income, body weight, hypertension, dyslipidemia, fasting glucose, and number of oral hypoglycemic agents used
CI, confidence interval
^aIncidence per 1000 person-years

ISSN: 1475-2840